Pharming Group to Present at Canaccord Genuity 45th Annual Growth Conference

Pharming Group will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12-13, 2025. Fabrice Chouraqui, CEO, will present on August 12 at 12:00pm EDT/18:00 CEST. For more information, contact Pharming's Investor Relations team at investor@pharming.com or your Canaccord Genuity representative. Pharming Group is a global biopharmaceutical company developing and commercializing innovative medicines for rare diseases.

Pharming Group (NASDAQ: PHAR) has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, USA. CEO Fabrice Chouraqui will deliver a presentation on Tuesday, August 12, 2025, at 12:00 PM EDT/18:00 CEST. The conference will take place on August 12-13, 2025.

Investors interested in one-on-one meetings with Pharming's management team can arrange them through the company's Investor Relations team or their Canaccord Genuity representative. For more information about the conference or to schedule a meeting, contact Pharming's Investor Relations team at investor@pharming.com or your Canaccord Genuity representative.

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

Pharming Group's participation in the Canaccord Genuity conference comes on the heels of strong financial performance in the second quarter of 2025. The company reported total revenues of US$93.2 million, a 26% increase compared to the same period in 2024. RUCONEST®, one of the company's key assets, saw a 28% increase in revenue to US$80.4 million, while Joenja® (leniolisib) revenue increased by 15% to US$12.8 million. The company also reported a positive operating profit of US$10.8 million compared to a US$3.1 million loss in the second quarter of 2024.

In addition to its strong financial performance, Pharming Group is making significant progress in its pipeline. The company has submitted a new drug application for leniolisib for the treatment of APDS in Japan and is working on options to mitigate the impact of recently announced U.S. tariffs. The company remains committed to expanding its studies to assess additional variants and estimate that 20% of VUS patients could ultimately be diagnosed with APDS.

For further public information, contact Pharming Group, Leiden, the Netherlands, at Michael Levitan, VP Investor Relations & Corporate Communications, T: +1 (908) 705 1696, E: investor@pharming.com.

References:
[1] https://www.stocktitan.net/news/PHARM/pharming-group-to-participate-in-august-investor-c7sowmehnh02.html
[2] https://www.biospace.com/press-releases/pharming-group-reports-second-quarter-and-first-half-2025-financial-results-and-provides-business-update